Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
Rothenburger, T., Thomas, D., Schreiber, Y., Wratil, P.R., Pflantz, T., Knecht, K., Digianantonio, K., Temple, J., Schneider, C., Baldauf, H.M., McLaughlin, K.M., Rothweiler, F., Bilen, B., Farmand, S., Bojkova, D., Costa, R., Ferreiros, N., Geisslinger, G., Oellerich, T., Xiong, Y., Keppler, O.T., Wass, M.N., Michaelis, M., Cinatl Jr., J.(2021) J Exp Clin Cancer Res 40: 317-317
- PubMed: 34641952 
- DOI: https://doi.org/10.1186/s13046-021-02093-4
- Primary Citation of Related Structures:  
7S2Y - PubMed Abstract: 
SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1.
Organizational Affiliation: 
Institute for Medical Virology, Goethe-University, Frankfurt am Main, Germany.